Pilar Escribano Subías to Walk Test
This is a "connection" page, showing publications Pilar Escribano Subías has written about Walk Test.
Connection Strength
0.160
-
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4).
Score: 0.160